GlassScriptPhysician profile
Tina Cheng
NPI 1013174499
$6,306.77
in general payments reported to CMS, 2019-2025
45 companies · $2,645 in 2025
The $2,645 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.48 · 2022: $290 · 2023: $1,651 · 2024: $1,708 · 2025: $2,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,003.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $542.12 | 2022-2025 | Strensiq, Koselugo |
| Novo Nordisk INC | $541.04 | 2022-2025 | Sogroya, Wegovy |
| Insulet Corporation | $508.53 | 2024-2025 | Omnipod |
| Biomarin Pharmaceutical INC. | $440.05 | 2023-2025 | Voxzogo 1.2mg, Palynziq |
| Tolmar, INC. | $377.41 | 2023-2025 | Fensolvi |
| Azurity Pharmaceuticals, INC. | $371.86 | 2023-2025 | Triptodur, Triptodur |
| Sanofi-Aventis U.S. LLC | $369.67 | 2024-2025 | |
| Abbvie INC. | $360.31 | 2023-2025 | Lupron Depot |
| Abbott Laboratories | $256.79 | 2023-2025 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $250.60 | 2024-2025 | Skytrofa |
| Xeris Pharmaceuticals, INC. | $213.96 | 2022-2025 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $158.58 | 2024-2025 | Unithroid |
| Neurocrine Biosciences, INC. | $150.32 | 2025 | |
| Neurelis, INC. | $142.73 | 2023-2025 | Valtoco |
| Amphastar Pharmaceuticals, INC. | $139.29 | 2024-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $121.72 | 2022-2023 | |
| Corium, LLC | $119.07 | 2023-2025 | Azstarys |
| Grifols USA, LLC | $109.30 | 2024-2025 | Xembify |
| Acadia Pharmaceuticals INC | $104.87 | 2023-2024 | Daybue |
| Tandem Diabetes Care, INC. | $96.89 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ironshore Pharmaceuticals INC. | $83.87 | 2023-2024 | Jornay Pm |
| Ucb, INC. | $83.61 | 2024-2025 | Briviact, Fintepla, Nayzilam |
| Soleno Therapeutics, INC. | $78.85 | 2025 | Vykat Xr |
| Medtronic, INC. | $59.27 | 2024 | Minimed 780g |
| Takeda Pharmaceuticals U.S.A., INC. | $59.21 | 2024-2025 | Eohilia |
| Qol Medical, LLC | $54.94 | 2025 | Sucraid |
| Philips North America LLC | $46.56 | 2025 | Vest Therapy Und |
| Endo USA, INC. | $41.93 | 2024 | Supprelin |
| Pfizer INC. | $41.78 | 2023-2025 | |
| Mirum Pharmaceuticals, INC. | $40.78 | 2023-2025 | Livmarli, Cholbam |
| Tolmar Pharmaceuticals, INC. | $39.85 | 2022 | |
| Collegium Pharmaceutical, INC. | $37.81 | 2025 | Jornay Pm |
| Sobi, INC | $31.24 | 2023 | |
| Glaxosmithkline, LLC. | $27.47 | 2023 | Nucala |
| Supernus Pharmaceuticals, INC. | $26.84 | 2024 | Qelbree |
| Catalyst Pharmaceuticals, INC. | $22.44 | 2024 | |
| Neos Therapeutics, LP | $19.94 | 2023 | Cotempla Xr-Odt |
| Dexcom, INC. | $19.36 | 2023 | Dexcom G6 Transmitter |
| Baxter Healthcare | $19.30 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Phadia US INC. | $18.24 | 2023 | Immunocap |
| Aquestive Therapeutics, INC. | $18.22 | 2025 | |
| Ironwood Pharmaceuticals, INC | $17.79 | 2024 | |
| Beta Bionics, INC. | $15.23 | 2024 | Ilet Bionic Pancreas |
| Janssen Biotech, INC. | $13.65 | 2025 | Tremfya |
| Ultragenyx Pharmaceutical INC. | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.